Catch up with the latest happenings at Terremoto.

Press Releases

Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.

In the News

Nothing Found

Sorry, no posts matched your criteria